The Effect of Frailty on Balance, Activities of Daily, and Exercise Capacity in COPD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-01

Study Completion Date

2019-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to demonstrate whether balance, cognition and activities of daily living have changed in COPD patients with and without frailty.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

COPD is a common, preventable and treatable disease characterized by progressive respiratory symptoms and airflow limitation. Frailty defines a clinical syndrome characterized by multiple system effects, leading to decreased functional reserve and increased sensitivity to dependence or mortality following minor stress events. Inflammation, lack of physical activity, reduced exercise efficiency and maximum oxygen uptake may contribute to the development of frailty in patients with COPD. Balance, cognition and activities of daily living are associated with COPD.

This study will evaluate the effect of frailty on balance, cognition and activities of daily living in patients with COPD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Frailty

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

COPD Frailty Balance Cognition Activities of Daily Living

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Frail patients with COPD

No intervention

No interventions assigned to this group

Non-frail patients with COPD

No intervention

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COPD patients who have been clinically stable for the last four weeks and who have not undergone drug change for the last four weeks
* Being 55 years of age or older
* Accepted to participate in the study (Able and wililing to complete the informed consent process)
* Co-operate
* Patients with COPD who are ambulant without support or an assistive device

Exclusion Criteria

* Neurological, cardiac or orthopedic diseases
* Other chronic diseases that may affect balance and walking

Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Deniz Inal-Ince

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Deniz Inal-Ince, PhD

Role: PRINCIPAL_INVESTIGATOR

Hacettepe University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hacettepe University Faculty of Health Sciences Department of Physiotherapy and Rehabilitation

Ankara, Sihhiye, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GO 18/83-22

Identifier Type: -

Identifier Source: org_study_id